ERBB2 and triple-negative breast carcinoma: Patients with hormone receptor–positive/human epidermal growth factor receptor 2 (HER2)/neu–negative breast carcinoma (hormone receptor–positive/HER2– BRCA, n = 168), triple-negative breast carcinoma (TN BRCA, n = 55), and ovarian carcinoma (OVCA, n = 90) had significantly better OS with high compared with low CD8+ and/or CD8+PD-1+ cells (P < .05, Figs 3A-3C).